HUTCHMED (China) (HMDCF) Receivables - Net (2015 - 2026)
HUTCHMED (China)'s (HMDCF) quarterly Receivables - Net came in at $117.6 million in Q2 2026, down 20.01% year-over-year from $147.0 million in Q2 2025, and down 7.25% quarter-over-quarter from $126.8 million in Q4 2025.
Analysis
HUTCHMED (China) (HMDCF) Receivables - Net (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Receivables - Net for 12 consecutive years, with $117.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Receivables - Net fell 20.01% year-over-year to $117.6 million in Q2 2026; TTM through Jun 2026 was $117.6 million, a 20.01% decrease from a year earlier, with the FY2025 full-year figure at $126.8 million, changed N/A from the prior year.
- Receivables - Net was $117.6 million for Q2 2026 at HUTCHMED (China), down from $126.8 million in the prior quarter.
- Over five years, Receivables - Net peaked at $156.9 million in Q2 2024 and troughed at $8.6 million in Q4 2023.
- A 5-year average of $96.9 million and a median of $122.2 million in 2025 frame the typical range for Receivables - Net.
- Across the five-year window, Receivables - Net surged 313.05% in 2022 and fell 27.66% in 2023, its largest moves.
- Over 5 years, Receivables - Net stood at $11.9 million in 2022, then slipped by 27.66% to $8.6 million in 2023, then surged by 1719.53% to $156.9 million in 2024, then decreased by 19.22% to $126.8 million in 2025, then retreated by 7.25% to $117.6 million in 2026.
- The last three Receivables - Net figures came in at $117.6 million (Q2 2026), $126.8 million (Q4 2025), and $147.0 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 117.56 Mn |
| Dec 31, 2025 | 126.75 Mn |
| Jun 30, 2025 | 146.97 Mn |
| Jun 30, 2024 | 156.92 Mn |
| Dec 31, 2023 | 8.62 Mn |
| Jun 30, 2023 | 129.20 Mn |
| Dec 31, 2022 | 11.92 Mn |
| Jun 30, 2022 | 77.08 Mn |
| Dec 31, 2021 | -5.60 Mn |
| Jun 30, 2021 | 57.98 Mn |
| Mar 31, 2021 | 53.13 Mn |
| Dec 31, 2020 | -9.60 Mn |
| Jun 30, 2020 | 44.63 Mn |
| Dec 31, 2019 | -2.73 Mn |
| Sep 30, 2019 | 40.38 Mn |
| Jun 30, 2019 | 42.78 Mn |
| Mar 31, 2019 | 42.36 Mn |
| Dec 31, 2018 | 2.39 Mn |
| Jun 30, 2018 | 44.72 Mn |
| Dec 31, 2017 | 6.98 Mn |